Abstract
Recent immune therapy with checkpoint inhibitors (CPIs) has demonstrated remarkable antitumor effects on specific tumors, such as malignant lymphoma and non-small cell lung carcinoma. By contrast, CPIs cause an imbalance in the immune system, triggering a wide range of immunological side effects termed immune-related adverse effects (irAEs). Here, we report a rare case of optic neuritis and hypopituitarism during anti-programmed death-ligand 1 (PD-L1) antibody treatment. A patient with non-small cell lung carcinoma received anti-PD-L1 antibody treatment every 3 weeks; however, the patient started experiencing headaches, general fatigue, anorexia, and diarrhea approximately 1 year after the initiation of the treatment. Moreover, sudden visual loss of the right eye occurred 1 week after the interruption of the anti-PD-L1 antibody treatment. MRI findings showed gadolinium enhancement in the left optic nerve, but no enlargement of the pituitary gland and stalk. Laboratory data showed decreased serum adrenocorticotropic hormone (ACTH), cortisol, and free T4 levels, and a hormone tolerance test indicated hypopituitarism, hypothyroidism, and hypoadrenocorticism. The central scotoma caused by optic neuritis completely disappeared immed...Continue Reading
References
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Oct 23, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey S WeberY Ann Chen
Feb 27, 2014·OncoTargets and Therapy·Giuseppina Della Vittoria ScarpatiStefano Pepe
Mar 13, 2014·Endocrine-related Cancer·Mabel RyderJames A Fagin
Aug 1, 2014·The Journal of Clinical Endocrinology and Metabolism·Alexander T FajeLisa Nachtigall
Jun 13, 2015·Ophthalmic Plastic and Reconstructive Surgery·Claire A SheldonMadhura A Tamhankar
Sep 5, 2015·BMC Medicine·Anne BertrandThierry Schaeverbeke
Jan 15, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M MichotO Lambotte
Feb 21, 2016·Critical Reviews in Oncology/hematology·Sara GandiniMario Mandalà
May 3, 2016·Current Opinion in Oncology·Joëlle AntounIsabelle Cochereau
Oct 26, 2016·Journal for Immunotherapy of Cancer·Melissa A WilsonLeslie A Fecher
Feb 24, 2017·Frontiers in Pharmacology·Vivek KumarAbhinav B Chandra
Jul 14, 2017·Clinical Diabetes and Endocrinology·Alexander Faje
Jan 25, 2018·Journal of the Endocrine Society·Keitaro KanieYutaka Takahashi
Citations
Oct 2, 2020·The International Journal of Neuroscience·Olga E MakriConstantine D Georgakopoulos
Apr 24, 2019·Ocular Immunology and Inflammation·Carl W NobleH Nida Sen
Jun 5, 2020·British Journal of Clinical Pharmacology·Paola Maria CutroneoGianluca Trifirò
Nov 12, 2020·Eye and Brain·Caberry W YuJonathan A Micieli
Feb 29, 2020·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·Aneesha Ahluwalia, Anita A Kohli
Mar 2, 2021·Seminars in Ophthalmology·Loulwah Mukharesh, Bart K Chwalisz
Sep 2, 2020·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·Mikel Vicente-PascualAlicia Traveset-Maeso
Jun 22, 2021·Internal Medicine·Keita KawakadoShoichi Kuyama
Sep 11, 2021·Frontiers in Immunology·Lin Zhou, Xin Wei
Jan 5, 2021·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·Anna KabanovskiEdward Margolin
Dec 16, 2020·Neurology·Alberto VogrigJérôme Honnorat